Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 7Lymphoid 6Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Myeloid 1Genitourinary 1Classical hematology 1

Conditions

Renal Pelvis and Ureter Urothelial Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 106Specimen Handling 87pembrolizumab 81enzalutamide 64Nivolumab 62Gemcitabine 59Docetaxel 51Abiraterone Acetate 44apalutamide 43Radiosurgery 43Androgen Antagonists 43Prednisone 42darolutamide 40Cisplatin 38Biopsy 36Radiotherapy 34cabozantinib 32Carboplatin 30abiraterone 29Pluvicto 29Ipilimumab 29durvalumab 25Leuprolide 24enfortumab vedotin 23X-Rays 23Radiation 23olaparib 20atezolizumab 20Standard of Care 20avelumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
pegylated granulocyte colony-stimulating factor × Genitourinary × 90 days × Clear all
NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
131 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡